New hope for kids with rare cancer: sirolimus combo shows promise

NCT ID NCT06341998

Completed Disease control Sponsor: Shandong First Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new combination of drugs (sirolimus plus chemotherapy) in 32 children with recurrent or refractory yolk sac tumors, a rare type of germ cell tumor. The goal was to see if the combination could shrink tumors and improve survival. The treatment was given in cycles over several weeks, with regular monitoring of tumor markers and imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sirolimus combined with nab-paclitaxel, ifosfamide, and carboplatin
What this could lead to: If successful, this combination could offer a new treatment option for children with yolk sac tumors that have not responded to standard chemotherapy.
What could go wrong: This is a small, early-phase study with only 32 participants. The results may not apply to all patients, and the combination may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Endodermal Sinus Tumor germ cell tumor Neoplasms, Germ Cell and Embryonal yolk sac tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERM CELL TUMOR YOLK SAC TUMOR

Contacts and locations

Locations

Shandong Cancer Hospital and Institute

Jinan, Shandong, 250117, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.